---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-05-10T18:22:55.198529'
end_time: '2026-05-10T18:42:32.377162'
duration_seconds: 1177.18
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: AGR2
  gene_symbol: AGR2
  uniprot_accession: O95994
  protein_description: 'RecName: Full=Anterior gradient protein 2 homolog; Short=AG-2;
    Short=hAG-2; AltName: Full=HPC8; AltName: Full=Secreted cement gland protein XAG-2
    homolog; Flags: Precursor;'
  gene_info: Name=AGR2; Synonyms=AG2; ORFNames=UNQ515/PRO1030;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the AGR family. .
  protein_domains: AGR/TXD. (IPR051099); Thioredoxin-like_sf. (IPR036249); Thioredoxin_7
    (PF13899)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 42
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O95994
- **Protein Description:** RecName: Full=Anterior gradient protein 2 homolog; Short=AG-2; Short=hAG-2; AltName: Full=HPC8; AltName: Full=Secreted cement gland protein XAG-2 homolog; Flags: Precursor;
- **Gene Information:** Name=AGR2; Synonyms=AG2; ORFNames=UNQ515/PRO1030;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the AGR family. .
- **Key Domains:** AGR/TXD. (IPR051099); Thioredoxin-like_sf. (IPR036249); Thioredoxin_7 (PF13899)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AGR2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AGR2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AGR2** (gene ID: AGR2, UniProt: O95994) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O95994
- **Protein Description:** RecName: Full=Anterior gradient protein 2 homolog; Short=AG-2; Short=hAG-2; AltName: Full=HPC8; AltName: Full=Secreted cement gland protein XAG-2 homolog; Flags: Precursor;
- **Gene Information:** Name=AGR2; Synonyms=AG2; ORFNames=UNQ515/PRO1030;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the AGR family. .
- **Key Domains:** AGR/TXD. (IPR051099); Thioredoxin-like_sf. (IPR036249); Thioredoxin_7 (PF13899)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AGR2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AGR2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AGR2** (gene ID: AGR2, UniProt: O95994) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Research Report: Human **AGR2** (Anterior gradient protein 2 homolog; UniProt **O95994**) — functional annotation

### 1) Gene/protein identity verification (critical disambiguation)
The literature retrieved and analyzed consistently matches the UniProt entry **O95994** for **Homo sapiens AGR2**, described as an **anterior gradient (AGR) family** member with a **thioredoxin/PDI-like fold** and a **non-canonical active-site CXXS motif** centered on **Cys81** and a **C-terminal ER retention motif KTEL** (boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 10-13). This matches the target identity provided in the prompt and excludes unrelated “AGR2” symbols from non-human organisms.

### 2) Key concepts and definitions (current understanding)

#### 2.1 AGR2 as a specialized PDI/thioredoxin-like folding factor
AGR2 is widely characterized as a **protein disulfide isomerase (PDI)-family / thioredoxin-like** protein functioning in the **endoplasmic reticulum (ER)** to support folding and maturation of secretory proteins, particularly mucins (boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 10-13, boisteau2022anteriorgradientproteins pages 1-6). Its distinguishing biochemical feature is a **non-canonical CXXS active-site motif** (rather than the canonical PDI CXXC), with a **single key cysteine (Cys81)** that participates in disulfide chemistry with client proteins (boisteau2022anteriorgradientproteins pages 6-10, park2009theproteindisulfide pages 2-2, park2009theproteindisulfide pages 4-5).

#### 2.2 ER retention and trafficking: the KTEL motif and “weak retention”
AGR2 contains an atypical **C-terminal KTEL** ER-retention motif, which binds KDEL receptors **non-canonically**, and is repeatedly discussed as a mechanistic reason AGR2 can be retained in the ER yet still be prone to secretion/redistribution under certain conditions (boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 10-13). Replacing KTEL with canonical **KDEL** can drive stronger ER sequestration (boisteau2022anteriorgradientproteins pages 10-13, boisteau2022anteriorgradientproteins pages 6-10).

#### 2.3 Intracellular AGR2 vs extracellular AGR2 (eAGR2)
A current conceptual framework in reviews is that AGR2 exists as both an **intracellular ER-resident proteostasis factor** and an **extracellular/secreted form (eAGR2)** with distinct roles, particularly in cancer and inflammatory microenvironments (boisteau2022anteriorgradientproteins pages 10-13, boisteau2022anteriorgradientproteins pages 6-10, qu2024agr2thecovert pages 3-5). However, authoritative sources emphasize that the **mechanisms enabling secretion** and which extracellular functions are direct vs indirect consequences of ER proteostasis remain incompletely resolved (boisteau2022anteriorgradientproteins pages 6-10, qu2024agr2thecovert pages 16-18).

### 3) Core molecular functions: what AGR2 “does”

#### 3.1 Primary functional axis: mucin folding/processing and mucus barrier biology
A central, experimentally supported function of AGR2 is enabling **proper mucin biogenesis**, especially gel-forming mucins that require extensive disulfide bond formation.

* **Park et al., PNAS 2009 (Apr 2009; https://doi.org/10.1073/pnas.0808722106)** demonstrate AGR2 is **essential for intestinal mucus production** and mechanistically link AGR2 to **MUC2**: AGR2 co-immunoprecipitates with MUC2 in a **DTT-sensitive** manner consistent with disulfide linkage, and an AGR2 cysteine mutant (C81S) fails to associate, supporting the role of the **active-site cysteine** in mixed-disulfide formation with mucins (park2009theproteindisulfide pages 2-2, park2009theproteindisulfide pages 4-5). Agr2-deficient mice show near absence of detectable MUC2 protein despite mRNA still being present (though reduced), and show increased susceptibility to colitis-related pathology (park2009theproteindisulfide pages 2-2, park2009theproteindisulfide pages 4-5).

* **Worfolk et al., Antioxidants & Redox Signaling 2019 (Nov 2019; https://doi.org/10.1089/ars.2018.7647)** further supports mucin specificity by identifying **MUC5AC/B** as a major secretory client class in a cancer context, with AGR2 participating in disulfide-dependent complexes and client quality control (worfolk2019elucidationofthe pages 11-14).

Across reviews, these findings are summarized as AGR2 contributing to folding/maturation/secretion of **MUC2 and MUC5AC/B** and other mucins through PDI-like chemistry, most likely including **mixed disulfide intermediates** (boisteau2022anteriorgradientproteins pages 10-13, boisteau2022anteriorgradientproteins pages 6-10).

**Substrate specificity (practical interpretation):** AGR2’s best-supported “substrates/clients” are **cysteine-rich secreted mucins** (MUC2; MUC5AC/B) rather than small-molecule substrates typical of metabolic enzymes; its “reaction” is thiol–disulfide exchange supporting mucin oxidative folding (park2009theproteindisulfide pages 2-2, park2009theproteindisulfide pages 4-5, worfolk2019elucidationofthe pages 11-14).

#### 3.2 AGR2 as a regulator of goblet-cell UPR signaling via IRE1β (major 2023 development)
A major 2023 advance is the demonstration that AGR2 is not only a mucin folding factor, but also a **direct regulator of an epithelial stress sensor**, **IRE1β** (ERN2).

* **Cloots et al., EMBO Journal 2023 (Dec 2023; https://doi.org/10.1038/s44318-023-00015-y)** show AGR2 binds **IRE1β** (selectively vs IRE1α) and **inhibits IRE1β oligomerization/dimerization**, shifting it toward an **inactive monomeric state** and suppressing IRE1β endonuclease outputs including **XBP1 splicing** and RIDD-associated readouts (cloots2023activationofgobletcell pages 1-2, cloots2023activationofgobletcell pages 6-7, cloots2023activationofgobletcell pages 12-13). AGR2 depletion triggers spontaneous IRE1β activation, indicating AGR2 availability in the ER sets an activation threshold (cloots2023activationofgobletcell pages 1-2). Mechanistically, AGR2 monomeric mutants (E60A/K64A) can still bind and inhibit IRE1β dimerization, but **active-site/Cys81 disruption (C81S)** and a **disease-associated H117Y** variant abrogate binding/inhibition (cloots2023activationofgobletcell pages 7-8, cloots2023activationofgobletcell pages 11-12).

* **Neidhardt et al., EMBO Journal 2023 (Dec 2023; https://doi.org/10.1038/s44318-023-00014-z)** provide complementary biophysical evidence that AGR2 perturbs IRE1β luminal-domain dimerization kinetics and report an estimated **AGR2 concentration in goblet-cell ER of ~460 µM**, supporting physiological plausibility of a direct chaperone-like repression mechanism (neidhardt2023theire1βmediatedunfolded pages 29-35).

**Interpretation:** These EMBO Journal studies support a model where AGR2 plays a dual “proteostasis integrator” role in goblet cells: it assists mucin folding load and simultaneously **tunes IRE1β** signaling by repressing dimerization until folding demand shifts the balance (cloots2023activationofgobletcell pages 6-7, neidhardt2023theire1βmediatedunfolded pages 29-35).

### 4) Subcellular localization and secretion: where AGR2 acts

#### 4.1 ER localization with conditional secretion into mucus
AGR2 is predominantly ER-localized, but multiple primary studies show it can be present extracellularly.

* **Bergström et al., PLoS ONE 2014 (Aug 2014; https://doi.org/10.1371/journal.pone.0104186)** report AGR2 in **mouse and human gastrointestinal mucus** (∼18 kDa band) and show in cell culture that secretion is controlled by both the **single free cysteine (Cys81)** and the **KTEL** motif: WT AGR2 is ER-retained, whereas **C81S** or loss of KTEL (ΔKTEL) permits secretion into media (bergstrom2014agr2anendoplasmic pages 4-6). This supports a mechanistic link between redox/thiol state, ER retention, and extracellular appearance.

* Reviews synthesize that the **non-canonical KTEL** motif enables weaker retention (vs KDEL) and that ER stress, overexpression, or altered dimerization can promote secretion (boisteau2022anteriorgradientproteins pages 10-13, boisteau2022anteriorgradientproteins pages 6-10).

#### 4.2 Extracellular AGR2 in cancer microenvironments
Reviews and translational studies emphasize extracellular AGR2 (eAGR2) as a pro-tumor factor that is mechanistically separable from ER folding roles.

* The Oncogene 2022 review summarizes findings that tumor-derived eAGR2 can bind extracellular growth factors such as **VEGF** and **FGF2** and enhance activity, with implications for angiogenesis and therapy interactions (boisteau2022anteriorgradientproteins pages 43-48).

* The Biomolecules 2024 review describes eAGR2 as particularly relevant to tumor microenvironment interactions and highlights context-dependent roles that may differ from intracellular AGR2 (qu2024agr2thecovert pages 3-5).

### 5) Recent developments (prioritizing 2023–2024)

#### 5.1 2023: AGR2–IRE1β as a goblet-cell-specific UPR rheostat
The strongest mechanistic advance is the demonstration that AGR2 is a **direct, selective repressor of IRE1β** via physical interaction and inhibition of dimerization/endonuclase activity; importantly, this requires intact AGR2 structural features including **Cys81** and a disease-relevant residue **H117** (cloots2023activationofgobletcell pages 1-2, cloots2023activationofgobletcell pages 7-8).

#### 5.2 2024: expansion of AGR2 as a therapeutic target in PDAC and beyond
A highly translational 2024 study develops **high-affinity human monoclonal antibodies** against AGR2 and quantifies PDAC prevalence and outcome associations.

* **Robinson et al., Antibodies 2024 (Dec 2024; https://doi.org/10.3390/antib13040101)** report AGR2 protein expression in **~90% of PDAC** biopsies, with staining coverage **5–70%** of tissue cores, and higher expression with disease progression (robinson2024ahighaffinitymonoclonal pages 6-8). Using TCGA/GTEx comparisons (TCGA n=179; GTEx n=177), AGR2 mRNA is higher in PDAC (p<0.01) and high AGR2 expression associates with worse disease-free survival (**HR = 2.5; p = 0.016**, high n=107 vs low n=27) (robinson2024ahighaffinitymonoclonal pages 6-8, robinson2024ahighaffinitymonoclonal pages 8-10). The study describes affinity-matured anti-AGR2 mAbs with **low-picomolar** binding and demonstrates functional neutralization of AGR2-mediated adhesion/migration and disruption of binding to **LYPD3** (robinson2024ahighaffinitymonoclonal pages 1-2, robinson2024ahighaffinitymonoclonal pages 15-17).

### 6) Current applications and real-world implementations

#### 6.1 Biomarker applications (tissue and potential fluid assays)
AGR2 is proposed and actively evaluated as a tissue biomarker in PDAC and other epithelial cancers.

* In PDAC, AGR2 is near-ubiquitously present in tumor tissue (~90%) and absent in normal pancreas in the analyzed cohorts, supporting diagnostic discrimination and stratification, with prognostic association via disease-free survival hazard ratio (robinson2024ahighaffinitymonoclonal pages 6-8, robinson2024ahighaffinitymonoclonal pages 8-10).

* Reviews additionally describe AGR2 as being secreted during pancreatic cancer development and discuss serum-based biomarker work and biosensor efforts, including an ultrasensitive AGR2 detection approach (femtogram detection) using monoclonal antibody-modified electrodes (boisteau2022anteriorgradientproteins pages 43-48).

#### 6.2 Therapeutic targeting (preclinical)
Current “real-world” use is predominantly **preclinical**, centered on targeting **extracellular AGR2** while recognizing potential toxicity/limitations of targeting ER-resident AGR2.

* The Oncogene 2022 review emphasizes that targeting ER-resident AGR2 may be problematic due to physiological roles (e.g., mucus barrier), but **secreted/cytosolic AGR2** may be more actionable; it summarizes multiple anti-AGR2 monoclonal antibody studies that reduce tumor growth/metastasis in animal models and may synergize with chemotherapy (boisteau2022anteriorgradientproteins pages 21-24, boisteau2022anteriorgradientproteins pages 43-48).

* Robinson et al. 2024 provide concrete implementation of this concept by generating high-affinity antibodies that neutralize AGR2-mediated pro-migratory effects and block AGR2 interactions (robinson2024ahighaffinitymonoclonal pages 1-2, robinson2024ahighaffinitymonoclonal pages 15-17).

#### 6.3 Clinical trials status
In the clinical-trials retrieval performed here, the “AGR2” query did not return an AGR2-targeted therapeutic trial; retrieved trials were unrelated to AGR2 as an intervention target (clinical-trials tool output not AGR2-specific). Therefore, based on the retrieved evidence, AGR2-targeted clinical translation remains largely **preclinical/early translational** in the sources examined (qu2024agr2thecovert pages 12-13, boisteau2022anteriorgradientproteins pages 43-48, robinson2024ahighaffinitymonoclonal pages 1-2).

### 7) Statistics and quantitative data highlights (recent studies)
Key quantitative results from recent and mechanistic studies include:

* **Goblet-cell ER AGR2 concentration:** ~**460 µM** (Neidhardt et al., EMBO J 2023) (neidhardt2023theire1βmediatedunfolded pages 29-35).
* **PDAC prevalence:** AGR2 protein in **~90%** of PDAC biopsies; staining **5–70%** of tissue cores (Robinson et al., 2024) (robinson2024ahighaffinitymonoclonal pages 6-8, robinson2024ahighaffinitymonoclonal pages 1-2).
* **Outcome association:** high AGR2 mRNA associated with worse disease-free survival (**HR 2.5**, **p=0.016**; high n=107 vs low n=27; TCGA/GTEx comparison n=179 vs 177, p<0.01) (robinson2024ahighaffinitymonoclonal pages 6-8, robinson2024ahighaffinitymonoclonal pages 8-10).
* **Mucin biology (airway model):** in allergen-challenged Agr2−/− mice, **MUC5AC −50.3%** and **MUC5B −56.1%** protein reductions without significant mRNA changes, supporting post-transcriptional processing control (Schroeder et al., 2012) (schroeder2012agr2isinduced pages 5-6).

### 8) Expert analysis and synthesis (authoritative consensus and open questions)

#### 8.1 Consensus
Across authoritative reviews and primary studies, the strongest consensus is that AGR2’s **primary physiological role** is as an **ER proteostasis factor for mucin-producing epithelial cells**, where it supports **mucin folding/processing** via thiol–disulfide exchange and participates in specialized ER homeostasis programs (park2009theproteindisulfide pages 2-2, park2009theproteindisulfide pages 4-5, boisteau2022anteriorgradientproteins pages 6-10). The 2023 EMBO Journal papers refine this by adding a direct, selective regulatory link to **IRE1β**, establishing AGR2 as part of a dedicated goblet-cell proteostasis regulatory module (cloots2023activationofgobletcell pages 1-2, neidhardt2023theire1βmediatedunfolded pages 29-35).

#### 8.2 Controversies and unresolved mechanisms
Key unresolved issues highlighted by authoritative synthesis include:

* **Mechanism of secretion:** AGR2 has an ER-retention signal (KTEL) yet is detectably extracellular (mucus; tumor microenvironment). Evidence points to weak/non-canonical KTEL retention plus redox/thiol state (Cys81) and ER stress/dimerization state as determinants, but the exact trafficking pathways are not fully unified across models (bergstrom2014agr2anendoplasmic pages 4-6, boisteau2022anteriorgradientproteins pages 6-10, qu2024agr2thecovert pages 16-18).

* **Functional meaning of extracellular AGR2:** eAGR2 is repeatedly linked to pro-tumor signaling (migration, angiogenesis, stromal effects), but how much reflects a regulated extracellular biology vs an ER-proteostasis spillover/adaptation remains a major interpretive question (boisteau2022anteriorgradientproteins pages 43-48, qu2024agr2thecovert pages 3-5, boisteau2022anteriorgradientproteins pages 6-10).

* **Context dependence in cancer:** Reviews note that AGR2 can correlate with aggressiveness in many tumors yet show context-specific prognostic associations, highlighting that localization (ER vs cytosol vs extracellular) and tissue type likely determine functional directionality (qu2024agr2thecovert pages 16-18, qu2024agr2thecovert pages 2-3).

### 9) Structured summary artifact
The following table consolidates the functional annotation, mechanisms, and key quantitative findings for AGR2:

| Aspect | Summary |
|---|---|
| Identity/domains | **Human AGR2 = anterior gradient protein 2 homolog, UniProt O95994**, a ~175 aa/~20 kDa **AGR-family, PDI/thioredoxin-like ER protein** with a thioredoxin fold; reported as monomeric or homodimeric and involved in secretory/transmembrane protein biogenesis in the ER. Central sources: Boisteau et al., **2022**, *Oncogene*, https://doi.org/10.1038/s41388-022-02452-1; Qu et al., **2024**, *Biomolecules*, https://doi.org/10.3390/biom14070743 (boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 1-6, qu2024agr2thecovert pages 2-3) |
| Catalytic motif | AGR2 contains a **non-canonical CXXS active-site motif** centered on **Cys81** (positions 81–84), distinguishing it from canonical PDI CXXC motifs; Cys81 is required for several client/regulatory interactions, while monomer–dimer behavior also involves **E60/K64**. Mutation **C81S** disrupts key regulatory functions and can promote secretion. Central sources: Boisteau et al., **2022**, https://doi.org/10.1038/s41388-022-02452-1; Cloots et al., **2023**, *EMBO J*, https://doi.org/10.1038/s44318-023-00015-y (boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 10-13, cloots2023activationofgobletcell pages 7-8, cloots2023activationofgobletcell pages 11-12) |
| Localization/retention | AGR2 is primarily an **ER-resident chaperone/PDI-like protein** carrying a **C-terminal KTEL ER-retention motif** that binds KDEL receptors non-canonically; this relatively weak retention helps explain why AGR2 can also traffic through the secretory pathway and be secreted under stress or when retention/folding is altered. Central sources: Boisteau et al., **2022**, https://doi.org/10.1038/s41388-022-02452-1; Worfolk et al., **2019**, *Antioxid Redox Signal*, https://doi.org/10.1089/ars.2018.7647 (boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 10-13, worfolk2019elucidationofthe pages 11-14, qu2024agr2thecovert pages 2-3) |
| Key clients/substrates | Best-supported client class is **mucins**: AGR2 is required for proper folding/maturation/secretion of **MUC2, MUC5AC, MUC5B** and can form mixed disulfide-linked complexes with mucins; Worfolk et al. identify **MUC5AC/B** as principal secretory clients in esophageal adenocarcinoma cells. Additional reported interactors include other PDIs, EpCAM, CALU, RCN1, cathepsins, and SQSTM1. Central sources: Worfolk et al., **2019**, https://doi.org/10.1089/ars.2018.7647; Boisteau et al., **2022**, https://doi.org/10.1038/s41388-022-02452-1 (worfolk2019elucidationofthe pages 11-14, boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 10-13, qu2024agr2thecovert pages 2-3) |
| UPR/IRE1β mechanism | Recent mechanistic work shows AGR2 is a **goblet-cell mucin chaperone that directly binds IRE1β**, shifts it toward an **inactive monomeric state**, **disrupts/prevents dimerization**, and suppresses **endonuclease outputs** including **XBP1 splicing** and RIDD-like signaling. AGR2 depletion causes spontaneous IRE1β activation; **C81S** and disease-associated **H117Y** mutants lose binding/inhibitory activity. Neidhardt et al. estimate AGR2 concentration in goblet-cell ER at **~460 µM**. Central sources: Cloots et al., **2023**, https://doi.org/10.1038/s44318-023-00015-y; Neidhardt et al., **2023**, *EMBO J*, https://doi.org/10.1038/s44318-023-00014-z (cloots2023activationofgobletcell pages 7-8, cloots2023activationofgobletcell pages 10-11, cloots2023activationofgobletcell pages 11-12, cloots2023activationofgobletcell pages 12-13, cloots2023activationofgobletcell pages 6-7, cloots2023activationofgobletcell pages 1-2, neidhardt2023theire1βmediatedunfolded pages 29-35) |
| Secretion/extracellular roles | Although ER-enriched, AGR2 can be released as **extracellular AGR2 (eAGR2)**, especially with ER stress, overexpression, or altered retention/dimer state. Secreted AGR2 has been linked to **inflammation, proliferation, angiogenesis, migration, metastasis**, and binding to extracellular growth factors such as **VEGF** and **FGF2**; reviews emphasize that eAGR2 may have functions distinct from intracellular AGR2. Central sources: Boisteau et al., **2022**, https://doi.org/10.1038/s41388-022-02452-1; Qu et al., **2024**, https://doi.org/10.3390/biom14070743 (boisteau2022anteriorgradientproteins pages 43-48, boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 10-13, qu2024agr2thecovert pages 3-5, robinson2024ahighaffinitymonoclonal pages 19-20) |
| Cancer relevance | AGR2 is widely implicated in epithelial cancers, especially **digestive tract, pancreatic, hepatobiliary, colorectal, breast, prostate, and lung** malignancies. Reported pro-tumor activities include enhanced **adhesion, migration, invasion, metastasis, stemness, immune evasion/PD-L1 regulation**, and modulation of therapy response. Antibody-based neutralization of eAGR2 is now a concrete preclinical strategy. Central sources: Qu et al., **2024**, https://doi.org/10.3390/biom14070743; Robinson et al., **2024**, *Antibodies*, https://doi.org/10.3390/antib13040101; Boisteau et al., **2022**, https://doi.org/10.1038/s41388-022-02452-1 (boisteau2022anteriorgradientproteins pages 43-48, qu2024agr2thecovert pages 3-5, robinson2024ahighaffinitymonoclonal pages 19-20, robinson2024ahighaffinitymonoclonal pages 1-2, robinson2024ahighaffinitymonoclonal pages 6-8, robinson2024ahighaffinitymonoclonal pages 8-10) |
| Quantitative statistics | Recent quantified observations include: **~90% of PDAC biopsies** expressed AGR2, while normal pancreas was essentially negative; PDAC staining covered **5–70%** of tissue cores; matched PDAC cohort significance **p = 0.0025, n = 24**; TCGA/GTEx comparison **n = 179 vs 177, p < 0.01**; high AGR2 mRNA associated with worse disease-free survival (**HR 2.5, p = 0.016; high n = 107 vs low n = 27**); anti-AGR2 antibodies reached **<50 pM** binding, while precursor scFv EC50s included **4.7 ± 0.52 µg/mL** for scFv-15; AGR2 concentration in goblet-cell ER estimated at **~460 µM**. Central sources: Robinson et al., **2024**, https://doi.org/10.3390/antib13040101; Neidhardt et al., **2023**, https://doi.org/10.1038/s44318-023-00014-z (robinson2024ahighaffinitymonoclonal pages 1-2, robinson2024ahighaffinitymonoclonal pages 6-8, robinson2024ahighaffinitymonoclonal pages 15-17, robinson2024ahighaffinitymonoclonal pages 8-10, robinson2024ahighaffinitymonoclonal pages 10-12, neidhardt2023theire1βmediatedunfolded pages 29-35) |


*Table: This table summarizes the current evidence for human AGR2 (UniProt O95994), including its molecular identity, catalytic features, localization, key clients, IRE1β regulation, extracellular roles, cancer relevance, and quantitative findings from recent and foundational sources.*

### 10) References (URLs and publication dates emphasized in-text)
Key sources used in this report include:
* Park et al., **Apr 2009**, PNAS, https://doi.org/10.1073/pnas.0808722106 (park2009theproteindisulfide pages 2-2, park2009theproteindisulfide pages 4-5)
* Bergström et al., **Aug 2014**, PLoS ONE, https://doi.org/10.1371/journal.pone.0104186 (bergstrom2014agr2anendoplasmic pages 4-6)
* Worfolk et al., **Nov 2019**, Antioxid Redox Signal, https://doi.org/10.1089/ars.2018.7647 (worfolk2019elucidationofthe pages 11-14)
* Boisteau et al., **Sep 2022**, Oncogene (review), https://doi.org/10.1038/s41388-022-02452-1 (boisteau2022anteriorgradientproteins pages 6-10, boisteau2022anteriorgradientproteins pages 10-13, boisteau2022anteriorgradientproteins pages 43-48)
* Cloots et al., **Dec 2023**, EMBO J, https://doi.org/10.1038/s44318-023-00015-y (cloots2023activationofgobletcell pages 1-2)
* Neidhardt et al., **Dec 2023**, EMBO J, https://doi.org/10.1038/s44318-023-00014-z (neidhardt2023theire1βmediatedunfolded pages 29-35)
* Qu et al., **Jun 2024**, Biomolecules (review), https://doi.org/10.3390/biom14070743 (qu2024agr2thecovert pages 2-3, qu2024agr2thecovert pages 3-5)
* Robinson et al., **Dec 2024**, Antibodies, https://doi.org/10.3390/antib13040101 (robinson2024ahighaffinitymonoclonal pages 6-8, robinson2024ahighaffinitymonoclonal pages 8-10)


References

1. (boisteau2022anteriorgradientproteins pages 6-10): Emeric Boisteau, Céline Posseme, Federico Di Modugno, Julien Edeline, Cédric Coulouarn, Roman Hrstka, Andrea Martisova, Frédéric Delom, Xavier Treton, Leif A. Eriksson, Eric Chevet, Astrid Lièvre, and Eric Ogier-Denis. Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology. Oncogene, 41:4673-4685, Sep 2022. URL: https://doi.org/10.1038/s41388-022-02452-1, doi:10.1038/s41388-022-02452-1. This article has 14 citations and is from a domain leading peer-reviewed journal.

2. (boisteau2022anteriorgradientproteins pages 10-13): Emeric Boisteau, Céline Posseme, Federico Di Modugno, Julien Edeline, Cédric Coulouarn, Roman Hrstka, Andrea Martisova, Frédéric Delom, Xavier Treton, Leif A. Eriksson, Eric Chevet, Astrid Lièvre, and Eric Ogier-Denis. Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology. Oncogene, 41:4673-4685, Sep 2022. URL: https://doi.org/10.1038/s41388-022-02452-1, doi:10.1038/s41388-022-02452-1. This article has 14 citations and is from a domain leading peer-reviewed journal.

3. (boisteau2022anteriorgradientproteins pages 1-6): Emeric Boisteau, Céline Posseme, Federico Di Modugno, Julien Edeline, Cédric Coulouarn, Roman Hrstka, Andrea Martisova, Frédéric Delom, Xavier Treton, Leif A. Eriksson, Eric Chevet, Astrid Lièvre, and Eric Ogier-Denis. Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology. Oncogene, 41:4673-4685, Sep 2022. URL: https://doi.org/10.1038/s41388-022-02452-1, doi:10.1038/s41388-022-02452-1. This article has 14 citations and is from a domain leading peer-reviewed journal.

4. (park2009theproteindisulfide pages 2-2): Sung-Woo Park, Guohua Zhen, Catherine Verhaeghe, Yasuhiro Nakagami, Louis T. Nguyenvu, Andrea J. Barczak, Nigel Killeen, and David J. Erle. The protein disulfide isomerase agr2 is essential for production of intestinal mucus. Proceedings of the National Academy of Sciences, 106:6950-6955, Apr 2009. URL: https://doi.org/10.1073/pnas.0808722106, doi:10.1073/pnas.0808722106. This article has 509 citations and is from a highest quality peer-reviewed journal.

5. (park2009theproteindisulfide pages 4-5): Sung-Woo Park, Guohua Zhen, Catherine Verhaeghe, Yasuhiro Nakagami, Louis T. Nguyenvu, Andrea J. Barczak, Nigel Killeen, and David J. Erle. The protein disulfide isomerase agr2 is essential for production of intestinal mucus. Proceedings of the National Academy of Sciences, 106:6950-6955, Apr 2009. URL: https://doi.org/10.1073/pnas.0808722106, doi:10.1073/pnas.0808722106. This article has 509 citations and is from a highest quality peer-reviewed journal.

6. (qu2024agr2thecovert pages 3-5): Shen Qu, Weili Jia, Ye Nie, Wen Shi, Chao Chen, Zihao Zhao, and Wenjie Song. Agr2: the covert driver and new dawn of hepatobiliary and pancreatic cancer treatment. Biomolecules, 14:743, Jun 2024. URL: https://doi.org/10.3390/biom14070743, doi:10.3390/biom14070743. This article has 5 citations.

7. (qu2024agr2thecovert pages 16-18): Shen Qu, Weili Jia, Ye Nie, Wen Shi, Chao Chen, Zihao Zhao, and Wenjie Song. Agr2: the covert driver and new dawn of hepatobiliary and pancreatic cancer treatment. Biomolecules, 14:743, Jun 2024. URL: https://doi.org/10.3390/biom14070743, doi:10.3390/biom14070743. This article has 5 citations.

8. (worfolk2019elucidationofthe pages 11-14): Jack C. Worfolk, Steven Bell, Lee D. Simpson, Naomi A. Carne, Sarah L. Francis, Vibecke Engelbertsen, Adrian P. Brown, Julie Walker, Yirupaiahgari K. Viswanath, and Adam M. Benham. Elucidation of the agr2 interactome in esophageal adenocarcinoma cells identifies a redox-sensitive chaperone hub for the quality control of muc-5ac. Antioxidants &amp; Redox Signaling, 31:1117-1132, Nov 2019. URL: https://doi.org/10.1089/ars.2018.7647, doi:10.1089/ars.2018.7647. This article has 18 citations and is from a domain leading peer-reviewed journal.

9. (cloots2023activationofgobletcell pages 1-2): Eva Cloots, Phaedra Guilbert, Mathias Provost, Lisa Neidhardt, Evelien Van de Velde, Farzaneh Fayazpour, Delphine De Sutter, Savvas N Savvides, Sven Eyckerman, and Sophie Janssens. Activation of goblet-cell stress sensor ire1β is controlled by the mucin chaperone agr2. The EMBO Journal, 43:695-718, Dec 2023. URL: https://doi.org/10.1038/s44318-023-00015-y, doi:10.1038/s44318-023-00015-y. This article has 33 citations.

10. (cloots2023activationofgobletcell pages 6-7): Eva Cloots, Phaedra Guilbert, Mathias Provost, Lisa Neidhardt, Evelien Van de Velde, Farzaneh Fayazpour, Delphine De Sutter, Savvas N Savvides, Sven Eyckerman, and Sophie Janssens. Activation of goblet-cell stress sensor ire1β is controlled by the mucin chaperone agr2. The EMBO Journal, 43:695-718, Dec 2023. URL: https://doi.org/10.1038/s44318-023-00015-y, doi:10.1038/s44318-023-00015-y. This article has 33 citations.

11. (cloots2023activationofgobletcell pages 12-13): Eva Cloots, Phaedra Guilbert, Mathias Provost, Lisa Neidhardt, Evelien Van de Velde, Farzaneh Fayazpour, Delphine De Sutter, Savvas N Savvides, Sven Eyckerman, and Sophie Janssens. Activation of goblet-cell stress sensor ire1β is controlled by the mucin chaperone agr2. The EMBO Journal, 43:695-718, Dec 2023. URL: https://doi.org/10.1038/s44318-023-00015-y, doi:10.1038/s44318-023-00015-y. This article has 33 citations.

12. (cloots2023activationofgobletcell pages 7-8): Eva Cloots, Phaedra Guilbert, Mathias Provost, Lisa Neidhardt, Evelien Van de Velde, Farzaneh Fayazpour, Delphine De Sutter, Savvas N Savvides, Sven Eyckerman, and Sophie Janssens. Activation of goblet-cell stress sensor ire1β is controlled by the mucin chaperone agr2. The EMBO Journal, 43:695-718, Dec 2023. URL: https://doi.org/10.1038/s44318-023-00015-y, doi:10.1038/s44318-023-00015-y. This article has 33 citations.

13. (cloots2023activationofgobletcell pages 11-12): Eva Cloots, Phaedra Guilbert, Mathias Provost, Lisa Neidhardt, Evelien Van de Velde, Farzaneh Fayazpour, Delphine De Sutter, Savvas N Savvides, Sven Eyckerman, and Sophie Janssens. Activation of goblet-cell stress sensor ire1β is controlled by the mucin chaperone agr2. The EMBO Journal, 43:695-718, Dec 2023. URL: https://doi.org/10.1038/s44318-023-00015-y, doi:10.1038/s44318-023-00015-y. This article has 33 citations.

14. (neidhardt2023theire1βmediatedunfolded pages 29-35): Lisa Neidhardt, Eva Cloots, Natalie Friemel, Caroline A M Weiss, Heather P Harding, Stephen H McLaughlin, Sophie Janssens, and David Ron. The ire1β-mediated unfolded protein response is repressed by the chaperone agr2 in mucin producing cells. The EMBO Journal, 43:719-753, Dec 2023. URL: https://doi.org/10.1038/s44318-023-00014-z, doi:10.1038/s44318-023-00014-z. This article has 37 citations.

15. (bergstrom2014agr2anendoplasmic pages 4-6): Joakim H. Bergström, Katarina A. Berg, Ana M. Rodríguez-Piñeiro, Bärbel Stecher, Malin E. V. Johansson, and Gunnar C. Hansson. Agr2, an endoplasmic reticulum protein, is secreted into the gastrointestinal mucus. PLoS ONE, 9:e104186, Aug 2014. URL: https://doi.org/10.1371/journal.pone.0104186, doi:10.1371/journal.pone.0104186. This article has 97 citations and is from a peer-reviewed journal.

16. (boisteau2022anteriorgradientproteins pages 43-48): Emeric Boisteau, Céline Posseme, Federico Di Modugno, Julien Edeline, Cédric Coulouarn, Roman Hrstka, Andrea Martisova, Frédéric Delom, Xavier Treton, Leif A. Eriksson, Eric Chevet, Astrid Lièvre, and Eric Ogier-Denis. Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology. Oncogene, 41:4673-4685, Sep 2022. URL: https://doi.org/10.1038/s41388-022-02452-1, doi:10.1038/s41388-022-02452-1. This article has 14 citations and is from a domain leading peer-reviewed journal.

17. (robinson2024ahighaffinitymonoclonal pages 6-8): Reeder M. Robinson, Leticia Reyes, Benjamin N. Christopher, Ravyn M. Duncan, Rachel A. Burge, Julie Siegel, Patrick Nasarre, Pingping Wang, John P. O’Bryan, G. Aaron Hobbs, Nancy Klauber-DeMore, and Nathan G. Dolloff. A high-affinity monoclonal antibody against the pancreatic ductal adenocarcinoma target, anterior gradient-2 (agr2/pdia17). Antibodies, 13:101, Dec 2024. URL: https://doi.org/10.3390/antib13040101, doi:10.3390/antib13040101. This article has 0 citations.

18. (robinson2024ahighaffinitymonoclonal pages 8-10): Reeder M. Robinson, Leticia Reyes, Benjamin N. Christopher, Ravyn M. Duncan, Rachel A. Burge, Julie Siegel, Patrick Nasarre, Pingping Wang, John P. O’Bryan, G. Aaron Hobbs, Nancy Klauber-DeMore, and Nathan G. Dolloff. A high-affinity monoclonal antibody against the pancreatic ductal adenocarcinoma target, anterior gradient-2 (agr2/pdia17). Antibodies, 13:101, Dec 2024. URL: https://doi.org/10.3390/antib13040101, doi:10.3390/antib13040101. This article has 0 citations.

19. (robinson2024ahighaffinitymonoclonal pages 1-2): Reeder M. Robinson, Leticia Reyes, Benjamin N. Christopher, Ravyn M. Duncan, Rachel A. Burge, Julie Siegel, Patrick Nasarre, Pingping Wang, John P. O’Bryan, G. Aaron Hobbs, Nancy Klauber-DeMore, and Nathan G. Dolloff. A high-affinity monoclonal antibody against the pancreatic ductal adenocarcinoma target, anterior gradient-2 (agr2/pdia17). Antibodies, 13:101, Dec 2024. URL: https://doi.org/10.3390/antib13040101, doi:10.3390/antib13040101. This article has 0 citations.

20. (robinson2024ahighaffinitymonoclonal pages 15-17): Reeder M. Robinson, Leticia Reyes, Benjamin N. Christopher, Ravyn M. Duncan, Rachel A. Burge, Julie Siegel, Patrick Nasarre, Pingping Wang, John P. O’Bryan, G. Aaron Hobbs, Nancy Klauber-DeMore, and Nathan G. Dolloff. A high-affinity monoclonal antibody against the pancreatic ductal adenocarcinoma target, anterior gradient-2 (agr2/pdia17). Antibodies, 13:101, Dec 2024. URL: https://doi.org/10.3390/antib13040101, doi:10.3390/antib13040101. This article has 0 citations.

21. (boisteau2022anteriorgradientproteins pages 21-24): Emeric Boisteau, Céline Posseme, Federico Di Modugno, Julien Edeline, Cédric Coulouarn, Roman Hrstka, Andrea Martisova, Frédéric Delom, Xavier Treton, Leif A. Eriksson, Eric Chevet, Astrid Lièvre, and Eric Ogier-Denis. Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology. Oncogene, 41:4673-4685, Sep 2022. URL: https://doi.org/10.1038/s41388-022-02452-1, doi:10.1038/s41388-022-02452-1. This article has 14 citations and is from a domain leading peer-reviewed journal.

22. (qu2024agr2thecovert pages 12-13): Shen Qu, Weili Jia, Ye Nie, Wen Shi, Chao Chen, Zihao Zhao, and Wenjie Song. Agr2: the covert driver and new dawn of hepatobiliary and pancreatic cancer treatment. Biomolecules, 14:743, Jun 2024. URL: https://doi.org/10.3390/biom14070743, doi:10.3390/biom14070743. This article has 5 citations.

23. (schroeder2012agr2isinduced pages 5-6): Bradley W. Schroeder, Catherine Verhaeghe, Sung-Woo Park, Louis T. Nguyenvu, Xiaozhu Huang, Guohua Zhen, and David J. Erle. Agr2 is induced in asthma and promotes allergen-induced mucin overproduction. American journal of respiratory cell and molecular biology, 47 2:178-85, Dec 2012. URL: https://doi.org/10.1165/rcmb.2011-0421oc, doi:10.1165/rcmb.2011-0421oc. This article has 149 citations and is from a peer-reviewed journal.

24. (qu2024agr2thecovert pages 2-3): Shen Qu, Weili Jia, Ye Nie, Wen Shi, Chao Chen, Zihao Zhao, and Wenjie Song. Agr2: the covert driver and new dawn of hepatobiliary and pancreatic cancer treatment. Biomolecules, 14:743, Jun 2024. URL: https://doi.org/10.3390/biom14070743, doi:10.3390/biom14070743. This article has 5 citations.

25. (cloots2023activationofgobletcell pages 10-11): Eva Cloots, Phaedra Guilbert, Mathias Provost, Lisa Neidhardt, Evelien Van de Velde, Farzaneh Fayazpour, Delphine De Sutter, Savvas N Savvides, Sven Eyckerman, and Sophie Janssens. Activation of goblet-cell stress sensor ire1β is controlled by the mucin chaperone agr2. The EMBO Journal, 43:695-718, Dec 2023. URL: https://doi.org/10.1038/s44318-023-00015-y, doi:10.1038/s44318-023-00015-y. This article has 33 citations.

26. (robinson2024ahighaffinitymonoclonal pages 19-20): Reeder M. Robinson, Leticia Reyes, Benjamin N. Christopher, Ravyn M. Duncan, Rachel A. Burge, Julie Siegel, Patrick Nasarre, Pingping Wang, John P. O’Bryan, G. Aaron Hobbs, Nancy Klauber-DeMore, and Nathan G. Dolloff. A high-affinity monoclonal antibody against the pancreatic ductal adenocarcinoma target, anterior gradient-2 (agr2/pdia17). Antibodies, 13:101, Dec 2024. URL: https://doi.org/10.3390/antib13040101, doi:10.3390/antib13040101. This article has 0 citations.

27. (robinson2024ahighaffinitymonoclonal pages 10-12): Reeder M. Robinson, Leticia Reyes, Benjamin N. Christopher, Ravyn M. Duncan, Rachel A. Burge, Julie Siegel, Patrick Nasarre, Pingping Wang, John P. O’Bryan, G. Aaron Hobbs, Nancy Klauber-DeMore, and Nathan G. Dolloff. A high-affinity monoclonal antibody against the pancreatic ductal adenocarcinoma target, anterior gradient-2 (agr2/pdia17). Antibodies, 13:101, Dec 2024. URL: https://doi.org/10.3390/antib13040101, doi:10.3390/antib13040101. This article has 0 citations.

## Citations

1. worfolk2019elucidationofthe pages 11-14
2. cloots2023activationofgobletcell pages 1-2
3. boisteau2022anteriorgradientproteins pages 43-48
4. robinson2024ahighaffinitymonoclonal pages 6-8
5. boisteau2022anteriorgradientproteins pages 6-10
6. boisteau2022anteriorgradientproteins pages 10-13
7. boisteau2022anteriorgradientproteins pages 1-6
8. park2009theproteindisulfide pages 2-2
9. park2009theproteindisulfide pages 4-5
10. cloots2023activationofgobletcell pages 6-7
11. cloots2023activationofgobletcell pages 12-13
12. cloots2023activationofgobletcell pages 7-8
13. cloots2023activationofgobletcell pages 11-12
14. robinson2024ahighaffinitymonoclonal pages 8-10
15. robinson2024ahighaffinitymonoclonal pages 1-2
16. robinson2024ahighaffinitymonoclonal pages 15-17
17. boisteau2022anteriorgradientproteins pages 21-24
18. cloots2023activationofgobletcell pages 10-11
19. robinson2024ahighaffinitymonoclonal pages 19-20
20. robinson2024ahighaffinitymonoclonal pages 10-12
21. https://doi.org/10.1073/pnas.0808722106
22. https://doi.org/10.1089/ars.2018.7647
23. https://doi.org/10.1038/s44318-023-00015-y
24. https://doi.org/10.1038/s44318-023-00014-z
25. https://doi.org/10.1371/journal.pone.0104186
26. https://doi.org/10.3390/antib13040101
27. https://doi.org/10.1038/s41388-022-02452-1;
28. https://doi.org/10.3390/biom14070743
29. https://doi.org/10.1089/ars.2018.7647;
30. https://doi.org/10.1038/s41388-022-02452-1
31. https://doi.org/10.1038/s44318-023-00015-y;
32. https://doi.org/10.3390/biom14070743;
33. https://doi.org/10.3390/antib13040101;
34. https://doi.org/10.1038/s41388-022-02452-1,
35. https://doi.org/10.1073/pnas.0808722106,
36. https://doi.org/10.3390/biom14070743,
37. https://doi.org/10.1089/ars.2018.7647,
38. https://doi.org/10.1038/s44318-023-00015-y,
39. https://doi.org/10.1038/s44318-023-00014-z,
40. https://doi.org/10.1371/journal.pone.0104186,
41. https://doi.org/10.3390/antib13040101,
42. https://doi.org/10.1165/rcmb.2011-0421oc,